INNOVIVE Pharmaceuticals Presents Preliminary Data at American Society of Hematology Showing INNO-305 Elicits Immune Response in Patients with Myeloid and Thoracic Neoplasms
10 Dec 2007
Vaccine
ATLANTA--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today presented results from a pilot study examining INNO-305, a Wilms Tumor Protein (WT1) heteroclitic peptide immunotherapeutic vaccine, in patients with myeloid and thoracic neoplasms. Preliminary data from the pilot study suggests repeat administration with INNO-305 is well tolerated and immune response can be elicited following three vaccinations. The data were presented at the 49th American Society of Hematology (ASH) Annual Meeting in Atlanta.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.